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OBJECTIVES We sought to study the gene expression of chemokines and their corresponding receptors in
mononuclear blood cells (MNCs) from patients with chronic heart failure (CHF), both of
which were cross-sectional and longitudinal studies during therapy with intravenous immu-
noglobulin (IVIg).
BACKGROUND We have recently demonstrated that IVIg improves left ventricular ejection fraction (LVEF)
in patients with CHF. Based on the potential pathogenic role of chemokines in CHF, we
hypothesized that the beneficial effect of IVIg may be related to a modulatory effect on the
expression of chemokines and their receptors in MNCs.
METHODS We examined: 1) the gene expression of C, CC and CXC chemokines and their receptors in
MNCs from 20 patients with CHF and 10 healthy blood donors; and 2) the expression of
these genes in MNCs from 20 patients with CHF randomized in a double-blind fashion to
therapy with IVIg or placebo for 26 weeks.
RESULTS Our main findings in CHF were: 1) markedly raised gene expression of macrophage
inflammatory protein (MIP)-1a, MIP-1b and interleukin (IL)-8; 2) enhanced gene expres-
sion of their corresponding receptors; 3) modulation in a normal direction of this abnormal
chemokine and chemokine receptor gene expression during IVIg, but not during placebo
therapy; 4) down-regulation of MIP-1a, MIP-1b and IL-8 during IVIg at the protein level
in plasma; and 5) a correlation between down-regulation of MIP-1a gene expression and
improved LVEF during IVIg therapy.
CONCLUSIONS Our results further support a pathogenic role for chemokines in CHF and suggest that IVIg
may represent a novel therapeutic approach, with the potential to improve LVEF in patients
with CHF, possibly by modulatory effects on the chemokine network. (J Am Coll Cardiol
2001;38:187–93) © 2001 by the American College of Cardiology
Increasing evidence supports that inflammation is involved
in the pathogenesis of chronic heart failure (CHF). In-
creased plasma levels and myocardial expression of inflam-
matory cytokines are found in patients with CHF (1,2) and
have been shown to induce myocardial dysfunction in
various animal models (3,4). Chemokines are a family of
inflammatory cytokines characterized by their ability to
cause directed migration of leukocytes into inflamed tissue
(5,6), and recent studies suggest that these mediators may be
involved in the pathogenesis of CHF (7–9). Thus, myocar-
dial up-regulation of chemokines has been found in animal
models of heart failure, possibly inducing myocardial infil-
tration of mononuclear blood cells (MNCs), with the
development of pathologic changes characteristic of CHF
(10,11). Chronic, low-grade inflammation with infiltrating
leukocytes has also been found in the failing human myo-
cardium (12). By playing a crucial role in the activation and
recruitment of these cells, chemokines may indirectly lead to
damage and dysfunction of the cardiac muscle.
Intravenous immunoglobulin (IVIg) has been tried in a
wide range of immune-mediated disorders (13), and bene-
ficial effects have also been suggested in acute and peripar-
tum cardiomyopathy (14,15). We have recently demon-
strated that IVIg improves left ventricular ejection fraction
(LVEF) in patients with CHF (16), and we hypothesized
that the beneficial effect of IVIg may be partly related to the
modulatory effects on the chemokine expression. To further
elucidate the possible role of chemokines in the pathogen-
esis of CHF, we examined: 1) the gene expression of C, CC
and CXC chemokines and their corresponding receptors in
MNCs isolated from patients with CHF and healthy blood
donors; and 2) the expression of these genes in MNCs
collected during right-sided heart catheterization in patients
with CHF randomized in a double-blind fashion to receive
therapy with either IVIg or placebo for a total period of 26
weeks.
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METHODS
Patients. The MNCs were collected from 20 patients
participating in the IVIg study (Table 1) (16). Patients were
included in the IVIg study if they: 1) had chronic, stable
CHF for .6 months; 2) were classified in New York Heart
Association functional class II to III; 3) had LVEF ,40%;
4) had no changes in medication during the last three
months; and 5) were receiving optimal medical treatment.
Patients were not included if they had: 1) evidence of
myocardial infarction or unstable angina during the last six
months, or 2) significant concomitant disease, such as
infections, pulmonary disease or connective tissue disease.
The conventional cardiovascular treatment was not changed
in any of the patients during the study. The etiology of
CHF was classified as coronary artery disease (n 5 10) or
idiopathic dilated cardiomyopathy (n 5 10). For compari-
son, MNCs were isolated from peripheral venous blood
drawn from the antecubital vein in 10 healthy gender- and
age-matched control subjects. The study was approved by
the Regional Ethics Committee and conformed to the
Declaration of Helsinki. Written, informed consent was
obtained from each patient.
Preparation of IVIg. Octagam (Octapharma, Vienna,
Austria), produced from fresh-frozen plasma collected from
Norwegian blood banks, was dispensed in sterile water
containing 10% maltose (final IgG concentration of 50 g/l)
(16).
Design of the IVIg study. The study design has previously
been described (16). Briefly, after baseline measurements,
the patients were randomized to either IVIg or placebo (5%
glucose) in a double-blind fashion and stratified according
to etiology (i.e., coronary artery disease or idiopathic dilated
cardiomyopathy). Either IVIg or an equal volume of placebo
was given as induction therapy (one daily infusion of
0.4 g/kg body weight for five days), and thereafter as a
monthly infusion (0.4 g/kg for five months). Baseline
measurements were repeated at the end of the study (26
weeks, four weeks after the last IVIg or placebo infusion).
At baseline and at the end of the study, LVEF was assessed
by electrocardiographically synchronized, gated radionu-
clide ventriculography at rest (16), and blood samples from
the pulmonary artery and coronary sinus were collected
during right-sided heart catheterization. Plasma samples
from peripheral venous blood were obtained at baseline and
after one, three and five months. In addition, four patients
with CHF (not included in the IVIg study) underwent left-
and right-sided heart catheterization to examine the differ-
ences in chemokine gene expression between the femoral
vein, femoral artery and pulmonary artery, and in the
femoral vein between the start and end of the catheteriza-
tion procedure. Collection and storage of plasma were
performed as previously described (16).
Ribonuclease protection assay (RPA). The MNCs were
obtained from heparinized blood by Isopaque-Ficoll (Lym-
phoprep, Nycomed Pharma AS, Oslo, Norway) through
gradient centrifugation within 45 min. Total ribonucleic
acid (RNA) was extracted from frozen cells using RNeasy
columns (QIAGEN, Hilden, Germany) and stored in RNA
storage solution (Ambion, Austin, Texas) at 280°C until
used. Multiprobe template sets (hCK5, hCR5 and hCR6)
were available with reagents for in vitro transcription and
RPA (RiboQuant; Pharmingen, San Diego, California).
The RPA was used for the detection and quantification of
messenger RNA (mRNA) species, as previously described
(9).
Miscellaneous. Plasma levels of macrophage inflammatory
protein (MIP)-1a, MIP-1b and interleukin (IL)-8 were
measured by enzyme immunoassays (R&D Systems, Min-
neapolis, Minnesota). The numbers of CD21, CD41,
CD81 and CD191 lymphocytes and monocytes (CD141
cells) were determined by immunomagnetic quantification
(17).
Statistical analysis. Differences between the groups were
compared by using the Mann-Whitney rank-sum test for
unpaired data. In the paired situation, two-way repeated
measures analysis of variance was performed a priori; if the
Abbreviations and Acronyms
CCR 5 CC chemokine receptor
CHF 5 chronic heart failure
CXCR 5 CXC chemokine receptor
IL-8 5 interleukin-8
IVIg 5 intravenous immunoglobulin
LVEF 5 left ventricular ejection fraction
MIP-1a or -1b 5 macrophage inflammatory protein-1a;
or -1b
MNCs 5 mononuclear blood cells
(m)RNA 5 (messenger) ribonucleic acid
RPA 5 ribonuclease protection assay
Table 1. Clinical Characteristics of Patients With Congestive





Age (yr) 59 6 1.6 61 6 2.2
Gender (male/female) 8/2 7/3
NYHA functional class (II/III) 4/6 3/7
Cause of heart failure
CAD 5 5
IDCM 5 5
Duration of heart failure (yrs) 3.6 6 0.8 3.3 6 0.7
Left ventricular ejection fraction (%) 25 6 2 27 6 3
Exercise data (peak V˙O2, l/min) 1.30 6 0.10 1.16 6 0.08
N-terminal-pro-ANP (pmol/l) 2,280 6 384 2,150 6 450
Medications
ACE inhibitors 10 9




Data are presented as the mean value 6 SEM or number of patients or subjects.
ACE 5 angiotensin-converting enzyme; ANP 5 atrial natriuretic peptide;
CAD 5 coronary artery disease; IDCM 5 idiopathic dilated cardiomyopathy;
IVIg 5 intravenous immunoglobulin; NYHA 5 New York Heart Association.
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outcome was significant, the Wilcoxon signed rank test for
paired data was performed a posteriori. Correlations be-
tween variables were tested using the Spearman rank test.
The p values are two-sided and considered significant at
,0.05.
RESULTS
Changes in MNC’s chemokine gene expression in human
CHF. Of the eight chemokine genes tested, seven were
detected with RPA in patients with CHF and healthy blood
donors (Fig. 1). The gene expression of MIP-1a (;21-
fold), MIP-1b (;10-fold) and IL-8 (;36-fold), but not
regulated upon activation, normally T cell expressed and
secreted (RANTES), was markedly increased in the patients
compared with the healthy control subjects (Fig. 1). The
other chemokines were detected at very low levels in both
patients with CHF and control subjects.
In the patients with CHF, the mRNA level of MIP-1a
was significantly higher in MNCs from arterial blood
compared with cells from venous blood (;24% increase,
p , 0.05). Moreover, gene expression of this chemokine
was also significantly increased in cells from the coronary
sinus compared with those from the pulmonary artery
(;30% increase, p , 0.01). Furthermore, there were no
differences between peripheral and central venous blood in
patients with CHF and no significant induction of chemo-
kine genes during the catheterization procedure (data not
shown).
Changes in MNC’s chemokine receptor gene expression
in human CHF. Concomitant with the enhanced expres-
sion of MIP-1a, MIP-1b and IL-8, the gene expression of
their corresponding receptors (CC chemokine receptor
[CCR] 1, CCR5, CXC chemokine receptor [CXCR] 1 and
CXCR2) was also significantly increased in MNCs from
patients with CHF (Fig. 2). In addition, CCR2 (i.e., the
MCP-1 receptor) and CX3CR (the fractalkine receptor)
showed enhanced gene expression in CHF (Fig. 2). In
contrast, gene expression of chemokine receptors involved
in constitutive lymphocyte homing (i.e., CXCR5 and
CCR7) (6) was significantly reduced in patients with CHF
compared with healthy blood donors (Fig. 2).
Effect of IVIg therapy on chemokine and chemokine
receptor expression. Next, we examined whether IVIg
could modulate the enhanced expression of chemokines and
their corresponding receptors in patients with CHF receiv-
ing IVIg (n 5 10) or placebo (n 5 10) for 26 weeks (see
Methods section). The interaction between the time of
observation and chemokine gene expression was significant
for MIP-1a (p , 0.001) and MIP-1b (p , 0.01), but no
consistent interaction was seen for IL-8 gene expression
(p 5 0.08). Gene expression of MIP-1a and MIP-1b
significantly decreased during IVIg treatment, but not
during placebo; this decrease was seen in all but one patient
(Fig. 3). We also measured plasma levels of MIP-1a,
MIP-1b and IL-8 at baseline and after one, three and five
months of therapy. The interaction between the time of
observation and chemokine plasma levels was significant for
MIP-1a (p , 0.001), MIP-1b (p , 0.001) and IL-8 (p ,
0.05). Although these chemokines tended to increase in the
placebo group, they significantly decreased during IVIg
therapy, resulting in significant differences in changes be-
tween the groups for MIP-1a and MIP-1b (Fig. 4).
Moreover, there was also a significant interaction between
the time of observation and chemokine receptor gene
expression; CCR1 (p , 0.001), CCR5 (p , 0.01) and
CXCR1 (p , 0.05). Thus, the decrease in chemokine levels
Figure 1. Representative RNase protection assay (RPA) (A) and relative messenger ribonucleic acid (mRNA) levels (B) of chemokines in mononuclear
blood cells (MNCs) from 20 patients with chronic heart failure (CHF) and 10 healthy control subjects (CTR). Horizontal lines indicate mean values.
GAPDH 5 glyceraldehyde-3-phosphate dehydrogenase; I-309 5 inducible-309; IL-8 5 interleukin-8; IP-10 5 interferon g inducible protein-10;
MCP-1 5 monocyte chemoattractant protein-1; MIP-1a 5 macrophage inflammatory protein-1a; MIP-1b 5 macrophage inflammatory protein-1b;
RANTES 5 regulated upon activation, normally T cell expressed and secreted; rpL32 5 ribosomal protein L32.
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was accompanied by a significant decrease in their receptor
levels on MNCs (i.e., CCR1, CCR5 and CXCR1) during
IVIg, but not placebo, treatment (Fig. 5).
Chemokine and chemokine receptor gene expression in
MNCs in relation to LVEF. Gene expression of MIP-1a
(r 5 20.66, p , 0.01), MIP-1b (r 5 20.52, p , 0.05) and
their common receptor CCR1 (r 5 20.64, p , 0.01) was
inversely correlated with LVEF at baseline. We have
previously shown a significant increase in LVEF (five
ejection fraction units) after IVIg treatment, but not after
placebo, in these patients with CHF (16). Importantly, this
increase in LVEF was significantly correlated with the
decrease in MIP-1a mRNA levels during IVIg (Fig. 6).
DISCUSSION
Increased chemokine expression has been detected during
inflammation in most organs, resulting in a selective recruit-
ment of leukocyte subpopulations into inflamed tissue (5,6).
To the best of our knowledge, the present study is the first
to show markedly altered gene expression of several chemo-
kines and their corresponding receptors in MNCs from
patients with CHF, and notably, these abnormalities were
significantly modulated in a normal direction during IVIg
therapy. As for MIP-1a levels, down-regulation was signif-
icantly correlated with improved LVEF during such ther-
apy. These findings support a role for abnormal chemokine
activation in the pathogenesis of CHF and suggest that
IVIg may modulate such activity.
Figure 2. Relative messenger ribonucleic acid (mRNA) levels of CC
chemokine receptor (A) and CXC chemokine receptor (B) in mononuclear
blood cells (MNCs) from 20 patients with chronic heart failure (CHF) and
10 healthy control subjects (CTR). Horizontal lines indicate mean values.
rpL32 5 ribosomal protein L32.
Figure 3. Relative messenger ribonucleic acid (mRNA) levels of macro-
phage inflammatory protein-1a (MIP-1a) (A), macrophage inflammatory
protein-1b (MIP-1b) (B) and interleukin-8 (IL-8) (C) in mononuclear
blood cells from 20 patients with chronic heart failure before and after six
months (mo) of treatment with intravenous immunoglobulin (IVIg) (n 5
10) or placebo (n 5 10). As for MIP-1a (p , 0.01) and MIP-1b (p ,
0.01), there were also differences in changes between the two groups.
Horizontal lines indicate mean values; n.s. 5 not significant. rpL32 5
ribosomal protein L32.
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Enhanced gene expression of chemokines and their
receptors in MNCs from patients with CHF. In the
present study, we have shown increased gene expression of
both CC (i.e., MIP-1a and MIP-1b) and CXC chemo-
kines (i.e., IL-8) in MNCs from patients with CHF, with
particularly high expressions of MIP-1a and MIP-1b in
patients with a low LVEF. Moreover, chemokine expres-
sion was significantly enhanced in MNCs from arterial
versus venous blood and in MNCs from the coronary sinus
versus the pulmonary artery, suggesting an activation of
chemokine expression during passage through the lung and
Figure 4. Plasma levels of macrophage inflammatory protein-1a (MIP-
1a) (A), macrophage inflammatory protein-1b (MIP-1b) (B) and
interleukin-8 (IL-8) (C), given as the percent change from baseline
(MIP-1a: 25.2 6 2.0 pg/ml; MIP-1b: 93.4 6 4.5 pg/ml; IL-8: 22.8 6
1.8 pg/ml), in 20 patients with chronic heart failure before and at different
time points after initiating treatment with intravenous immunoglobulin
(n 5 10; solid circles) or placebo (n 5 10; open circles). Data are given
as the mean value 6 SEM. *p , 0.05; **p , 0.01 versus baseline; #p , 0.05
when comparing changes between intravenous immunoglobulin and placebo.
Figure 5. Relative messenger ribonucleic acid (mRNA) levels of chemo-
kine receptor (CCR) 1 (A), CCR5 (B) and CXCR1 (C) in mononuclear
blood cells from 20 patients with chronic heart failure before and after six
months (mo) of treatment with intravenous immunoglobulin (IVIg) (n 5
10) or placebo (n 5 10). As for CCR1 (p , 0.001) and CCR5 (p , 0.01),
there were also differences in changes between the two groups. Horizontal
lines indicate mean values; n.s. 5 not significant. rpL32 5 ribosomal
protein L32.
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heart circulation, respectively. Recent reports indicate that
chemokines are involved in the migration of MNCs into the
cardiovascular system in various disorders, such as athero-
sclerosis and myocarditis (5,6,11). These activated MNCs
may, in turn, damage the vessel wall and myocardium
through production of reactive oxygen species, proteolytic
enzymes and inflammatory cytokines (5,6). Thus, MIP-1a
knock-out mice do not develop cardiac lesions after Cox-
sackie virus B infection because of attenuated myocardial
recruitment of activated MNCs (18). We have recently
demonstrated high levels of MIP-1a and one of the
corresponding receptors (i.e., CCR1) in the human myo-
cardium, with particularly enhanced gene expression of
CCR1 in CHF (9). If the enhanced levels of MIP-1a and
its receptors also exist in MNCs infiltrating the failing
myocardium, our findings suggest a potential for interac-
tions between the myocardium and MNCs in CHF involv-
ing chemokines, possibly both directly and indirectly mod-
ulating cardiac function.
Intravenous immunoglobulin down-regulates enhanced
chemokine and chemokine receptor expression in CHF.
Currently, IVIg is widely used in patients with various
inflammatory disorders (13–15). How these disorders are
modulated by IVIg is poorly understood, but several non-
mutually exclusive modes of action may exist, such as
Fc-receptor blockade, complement inactivation and cyto-
kine modulation (13,16). Our study shows that modulation
of chemokine expression may also represent an important
mechanism of action of IVIg. The capacity to control
activation and movement of inflammatory cells suggests that
chemokines and their receptors might provide novel targets
for therapeutic intervention in a number of diseases char-
acterized by chronic inflammation. A series of chemokine
antagonists have been found to be effective in preventing the
development of various inflammatory diseases in animal
models (19). Our observation that IVIg down-regulates
several chemokines and their corresponding receptors in
patients with CHF, accompanied by improved LVEF, may
introduce IVIg as a potential novel therapeutic modality for
CHF and other cardiovascular disorders in which enhanced
chemokine activity may play a pathogenic role (e.g., myo-
carditis and unstable angina) (5,11,20). However, although
the present study suggests a potential role for chemokines in
the pathogenesis of CHF, a small number of patients were
studied, and the effect of IVIg on the chemokine network in
patients with CHF will have to be confirmed in future
studies.
Conclusions. The present study demonstrates markedly
altered gene expression of chemokine and chemokine re-
ceptor in MNCs from patients with CHF, and as for
MIP-1a and MIP-1b and their corresponding receptors,
enhanced expression was significantly correlated with de-
pressed LVEF. Notably, these chemokine abnormalities
were significantly modulated in a normal direction during
IVIg therapy, concomitant with a significant improvement
of LVEF. Our findings further support a role for chemo-
kines in the pathogenesis of CHF and suggest that IVIg
may represent a novel therapeutic approach, with the
potential to improve LVEF in patients with CHF, at least
partly by modulatory effects on the chemokine network.
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